Skip to content

Sugammadex and Cognitive Function

Effect of Sugammadex Versus Neostigmine/Atropine Combination on Cognitive Function After Elective Adult Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02419352
Enrollment
160
Registered
2015-04-17
Start date
2010-09-30
Completion date
2015-12-31
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Cognitive Dysfunction

Keywords

Cognitive function

Brief summary

Post operative cognitive dysfunction (POCD) is recognized as a frequent complication after both cardiac and non cardiac surgery, affecting approximately 1/3 of the patients. The aim of this study is to examine the possible effect of the novel reversal agent sugammadex versus neostigmine/ atropine combination on cognitive function of adult patients after elective surgery during the early post operative period as well as at discharge.

Interventions

DRUGSugammadex

Sponsors

Attikon Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients aged \>40 years old * ASA I-III * Patients scheduled for elective surgery with general anaesthesia.

Exclusion criteria

* Neuro-, vascular-, orthopedic- or cardiac surgery * Known psychiatric or disease of the CNS * History of craniotomy * Receiving tranquillisers or antidepressants on a regular basis pre-operatively * Alcoholism or drug dependence * History of stroke * Refusal of patient * Inability to read or write * MMSE \< 22 pre-operatively

Design outcomes

Primary

MeasureTime frame
Change in the Mini-Mental State Evaluation testPreoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively)
Change in the clock-drawing testPreoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively)
Change in the Isaacs set testPreoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively)

Secondary

MeasureTime frame
Time from reversal agent administration to extubationAfter reversal agent administration

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026